Concurrent alteration of p16 and PTEN tumor suppressor genes could be considered as potential molecular marker for specific subgroups of NSCLC patients

Andjelković, Tijana; Banković, Jasna; Milošević, Zorica; Stojšić, Jelena; Milinkovic, Vedrana; Pešić, Milica; Ruždijić, Sabera; Tanić, Nikola

doi:10.3233/cbm-2012-0257

Cited by 7 publications

(2 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Panani et al (2009) demonstrated that numerous abnormalities in chromosome 9 and CDKN2A deletion were detected by FISH in NSCLC patients. Andjelkovic et al (2011) proposed the concurrent alterations of both CDKN2A and PTEN as potential biomarkers for particular subgroups of NSCLC patients. Our data were in support of the antitumor properties of CDKN2A , deletion of which was notably detected in many lung cancer patients, and therefore, suggested a fundamental role in the tumorigenesis of this disease.…”

Section: Discussionmentioning

confidence: 99%

Loss of CDKN2A at chromosome 9 has a poor clinical prognosis and promotes lung cancer progression

Liu¹,

Zhuang²,

Huang³

et al. 2020

Molec Gen & Gen Med

View full text Add to dashboard Cite

Lung cancer is one of the most common human malignancies globally (Barnett, 2017). Based on Cancer Statistics 2012, there were 1.8 million new cases diagnosed and 1.6 million deaths claimed by this disease (Siegel et al., 2012), making lung cancer the most common cancer-related death in men while the second in women only after breast cancer. Histologically, lung cancer is mainly categorized into two types: small cell lung carcinoma (SCLC) and non-small cell lung cancer (NSCLC). Long-term tobacco smoking contributes to the huge majority of morbidity of lung cancer (Lin et al., 2008), and other recognized risk factors include combination of genetic abnormalities (Dai et al., 2019), radon gas, asbestos, and other forms

show abstract

Section: Discussionmentioning

confidence: 99%

Loss of CDKN2A at chromosome 9 has a poor clinical prognosis and promotes lung cancer progression

Liu¹,

Zhuang²,

Huang³

et al. 2020

Molec Gen & Gen Med

View full text Add to dashboard Cite

show abstract

“…It has been demonstrated that AKT acts as a survival kinase, and its expression increases in numerous types of cancer, including lung cancer (33). AKT may be activated by a loss of PTEN, which is a well-known tumor suppressor gene in various types of human cancer (34)(35)(36). It has been demonstrated that miRNAs contribute to cancer cell growth by regulating PTEN (37).…”

Section: Discussionmentioning

confidence: 99%

microRNA-664 enhances proliferation, migration and invasion of lung cancer cells

Zhu

Yuan

et al. 2017

Experimental and Therapeutic Medicine

View full text Add to dashboard Cite

Altered microRNA (miR) expression serves an important role in the development and progression of lung cancer. In the present study, the effect of miR-664 on proliferation, migration and invasion of lung cancer cells was assessed. The proliferation of lung cancer cells with an overexpression of miR-664 was examined via MTT assay. The Caspase-Glo3/7 assay was used to examine the effect of miR-664 on cisplatin-induced apoptosis in lung cancer cells. The migration and invasion of lung cancer cells were assessed by Transwell migration and matrigel invasion assays. Western blot analysis was used to examine the protein expression levels. miR-664 improved the proliferation of lung cancer cells and inhibited cisplatin-induced apoptosis of A549 and A427 cells. Furthermore, altered expression of miR-664 affected migration and invasion of lung cancer cells. In addition, a miR-664 mimic decreased E-cadherin expression and increased vementin and Snail expression in lung cancer cells. Notably, the expression level of protein kinase B in A549 cells was changed following altered expression of miR-664. The results of the present study suggest that miR-664 serves an essential role in tumor development and progression in lung cancer.

show abstract

PTEN and p16 genes as epigenetic biomarkers in oral squamous cell carcinoma (OSCC): a study on south Indian population

Sushma

Jamil²,

Kumar

et al. 2015

Tumor Biol.

View full text Add to dashboard Cite

Phosphatase and tensin homolog (PTEN) and p16INK4a (p16) genes are tumor suppressor genes, associated with epigenetic alterations. PTEN and p16 promoter hypermethylation is a major epigenetic silencing mechanism leading to cancer. The cooperation between PTEN and p16 in pathogenesis of cancers suggest that their combination might be considered as potential molecular marker for specific subgroups of patients. Hence, the present study aimed to investigate whether PTEN and p16 promoter methylations were involved in oral squamous cell carcinoma (OSCC) in south Indian subjects. DNA methylation quantitative analyses of the two candidate tumor suppressor genes PTEN and p16 were performed by methylation-specific polymerase chain reaction (MSP). Fifty OSCC biopsy samples and their corresponding non-malignant portions as controls were studied comparatively. The methylation status was correlated with the clinical manifestations. Twelve out of 50 patients (24 %) were found to be methylated for PTEN gene, whereas methylation of the p16 gene occurred in 19 out of 50 cases (38 %). A statistically significant result was obtained (P = <0.0001 and 0.017) for both PTEN and p16 genes. PTEN and p16 promoter methylation may be the main mechanism leading to the low expression of PTEN and p16 genes indicating the progress of tumor development. Our data suggest that a low PTEN and p16 expression due to methylation may contribute to the cancer progression and could be useful for prognosis of OSCC. Therefore, analysis of promoter methylation in such genes may provide a biomarker valuable for early detection of oral cancer.

show abstract

Concurrent alteration of p16 and PTEN tumor suppressor genes could be considered as potential molecular marker for specific subgroups of NSCLC patients

Cited by 7 publications

References 34 publications

Loss of CDKN2A at chromosome 9 has a poor clinical prognosis and promotes lung cancer progression

Loss of CDKN2A at chromosome 9 has a poor clinical prognosis and promotes lung cancer progression

microRNA-664 enhances proliferation, migration and invasion of lung cancer cells

PTEN and p16 genes as epigenetic biomarkers in oral squamous cell carcinoma (OSCC): a study on south Indian population

Contact Info

Product

Resources

About